Additionally, a randomized phase II trial of AZD-9833, a next-generation oral SERD and pure ERα antagonist, demonstrated a significant improvement in progression-free survival (PFS) compared to Fulvestrant in post-menopausal patients with ER + breast cancer who had previously received endocrine therapy (Turner et al., 2023). Here, ESR1 is linked to breast carcinoma.